Renaissance Technologies LLC Sells 188,600 Shares of Rezolute, Inc. (NASDAQ:RZLT)

Renaissance Technologies LLC reduced its holdings in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 67.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 89,700 shares of the company's stock after selling 188,600 shares during the period. Renaissance Technologies LLC owned approximately 0.15% of Rezolute worth $440,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in Rezolute by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock worth $2,535,000 after purchasing an additional 25,413 shares during the period. American Century Companies Inc. grew its position in Rezolute by 62.1% in the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock worth $316,000 after purchasing an additional 24,742 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in Rezolute in the 4th quarter valued at about $277,000. Virtu Financial LLC raised its position in shares of Rezolute by 58.0% in the third quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock worth $126,000 after buying an additional 9,551 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after purchasing an additional 9,000 shares during the last quarter. 82.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RZLT has been the topic of a number of recent analyst reports. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a report on Monday, February 10th. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of Rezolute in a research note on Monday, April 28th. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. Finally, JMP Securities upped their price objective on Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $26.43.

Insider Activity

In other Rezolute news, CEO Nevan C. Elam bought 12,302 shares of Rezolute stock in a transaction that occurred on Thursday, March 27th. The shares were bought at an average price of $2.85 per share, with a total value of $35,060.70. Following the acquisition, the chief executive officer now owns 224,119 shares in the company, valued at approximately $638,739.15. This trade represents a 5.81 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wladimir Hogenhuis purchased 10,000 shares of Rezolute stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the transaction, the director now directly owns 77,267 shares of the company's stock, valued at $363,154.90. This trade represents a 14.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 39,060 shares of company stock worth $130,694. Corporate insiders own 18.39% of the company's stock.

Rezolute Stock Down 0.8 %

Shares of Rezolute stock traded down $0.03 during trading on Friday, hitting $3.69. The stock had a trading volume of 170,430 shares, compared to its average volume of 843,232. Rezolute, Inc. has a 1 year low of $2.21 and a 1 year high of $6.19. The stock has a 50 day simple moving average of $3.26 and a 200 day simple moving average of $4.39. The company has a market capitalization of $223.37 million, a PE ratio of -3.02 and a beta of 1.01.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11. As a group, equities analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.